Setback for Cobenfy: Bristol Myers’ Schizophrenia Drug Misses Key Trial Mark

Cobenfy, a drug Bristol Myers Squibb acquired in a $14 billion deal, failed to show added benefits in patients with schizophrenia when used alongside standard treatments. Bristol Myers Squibb has announced that its schizophrenia drug Cobenfy did not meet the main goal in a late-stage clinical trial. The trial was designed to evaluate whether Cobenfy […]